The research analyzed data from 45 male SOF veterans undergoing a clinical treatment program using ibogaine, a hallucinogenic compound derived from the roots of a West African shrub, and 5-MeO-DMT, a psychedelic substance found in a number of plant species, that was carried out in
Participants that were screened comprised of 29% that were considered moderate-risk drinkers, 29% that were categorized as high-risk drinkers and 42% that were classified as severe-risk drinkers. The findings revealed that one month after treatment, there was a significant decrease in alcohol consumption with 24% of the participants being abstinent and 33% engaging in non-risky drinking. There still remained 42% that were considered still risky drinkers.
Respondents that refrained from alcohol consumption expressed a reduction in PTSD symptoms and improvements in cognitive functioning in their follow-up psychological assessments, one month after the treatment. According to the study's lead author
Following the publication of the research study, Armstong was featured in a recent exclusive interview with PsyPost, stating that 'evaluating other medication-assisted therapies (e.g., ketamine, psilocybin) among Special Operations Forces Veterans is necessary to determine which treatment is most beneficial for whom, and for which mental health conditions'[3].'The result of this study and its implications add further proof that psychedelic-assisted therapy has the potential to revolutionize the way we approach mental health and addiction. The Company commends the hardworking researchers and its courageous participants that have helped further paved the way for the advancement of psychedelic-based solutions that have ability to address today's problematic and pressing issues in society,' stated
In addition to the above the Company announces that it has entered into a debt settlement agreement (the 'Agreement') with an arms-length creditor of the Company. Pursuant to the Agreement, the Company has agreed to issue an aggregate amount of 135,570 common shares ('Common Shares') in the capital of the Company at a deemed price of
About
The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.
In addition to the development of psychedelics and psychedelic compounds,
Contact:
Email: info@core1labs.com
Tel: 1-888-452-6731
Cautionary Disclaimer Statement
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (
(C) 2023 Electronic News Publishing, source